Yu Min, Zhang Shuang, Huang Meijuan, Lu You
Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Mol Clin Oncol. 2014 Jul;2(4):567-570. doi: 10.3892/mco.2014.280. Epub 2014 Apr 16.
Maintenance therapy with pemetrexed is well tolerated and achieves prolonged progression-free and overall survival in patients with advanced lung adenocarcinoma. The echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) is a recently identified fusion oncogene that exists in ~5% of non-small-cell lung cancers (NSCLCs). It was demonstrated that ALK-positive NSCLCs exhibit a high response rate to the ALK inhibitor crizotinib. This is the case report of a patient with NSCLC harboring EML4-ALK rearrangement, who experienced slowly progressive disease within 4 years of maintenance treatment with pemetrexed and later exhibited a marked response to crizotinib. The sustained clinical benefits suggest further investigations on anticancer agent administration.
培美曲塞维持治疗耐受性良好，可延长晚期肺腺癌患者的无进展生存期和总生存期。棘皮动物微管相关蛋白样4（EML4）-间变性淋巴瘤激酶（ALK）是最近发现的一种融合致癌基因，约5%的非小细胞肺癌（NSCLC）中存在该基因。已证实ALK阳性的NSCLC对ALK抑制剂克唑替尼表现出高反应率。本文报告1例伴有EML4-ALK重排的NSCLC患者，该患者在接受培美曲塞维持治疗4年内病情缓慢进展，随后对克唑替尼表现出显著反应。持续的临床获益提示需进一步研究抗癌药物的给药方式。
